Redefining Drug Discovery: QureGenAI at the 2050 ConferenceAt the recent 2050 Conference

Redefining Drug Discovery: QureGenAI at the 2050 Conference
At the recent 2050 Conference, QureGenAI demonstrated how quantum computing is actively closing the "accuracy gap" in traditional drug discovery.
During his keynote, CEO Dr. Xiaoran Li highlighted a critical efficiency milestone: while the landmark drug Gleevec required 41 years to reach the market, QureGenAI navigated the same discovery and design phase for our QGB-02 pipeline in just one year, utilizing our quantum-classical hybrid simulation.
Our booth served as a primary hub for technical exchange and live interaction. We were honored to welcome CAS Academician Jian Wang, who visited the QureGenAI booth to learn about our hybrid computing architecture and technical roadmap. In parallel, Chief Architect Zhupeng Han conducted live platform demonstrations at the booth, showcasing the practical application of quantum AI in molecular design to a global audience of scientists and industry leaders.
With two Pre-IND and four PCC-stage pipelines currently in development, our focus remains sharp. By tackling the industry's fundamental bottlenecks, QureGenAI is dedicated to its founding vision: to build high-quality drugs that are truly commercially viable—to make great drugs that don't just work, but actually sell.

Видео Redefining Drug Discovery: QureGenAI at the 2050 ConferenceAt the recent 2050 Conference канала QureGenAI